Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628
Garcia, D. , Rathi, Sneha , Connors, Margaret A. , Grams, Michael P. , Vaubel, Rachael A. , Bakken, Katrina K. , Ott, Lauren L. , Carlson, Brett L. , Hu, Zeng , Decker, Paul A. , Eckel‐Passow, Jeanette E. , Zhong, Wei , Trzasko, Joshua D. , Herman, Margot , Elmquist, William F. , Remmes, Nicholas B. , Garcia, Darwin A , Grams, Michael P , Burgenske, Danielle M , Zhong, Wei , Trzasko, Joshua D , Herman, Michael G , Elmquist, William F , Remmes, Nicholas B , Sarkaria, Jann N , Vaubel, Rachael A , Bakken, Katrina K , Decker, Paul A. , Burgenske, Danielle M. , Sarkaria, Jann N.

Molecular Cancer Therapeutics | November 19, 2024 | Volume: 24 | Issue: 2 | Pages: 299-309

10.1158/1535-7163.mct-24-0664 | PMID 39559836 Get It

Abstract Ataxia Telangiectasia–mutated (ATM) inhibitors are being developed as radiosensitizers to improve the antitumor effects of radiotherapy, but ATM inhibition can also radiosensitize normal tissues. Therefore, understanding the elevated risk of normal tissue toxicities is critical for radiosensitizer development. This study focused on modeling the relationship between acute mucosal toxicity, radiation dose, fractionation schedule, and radiosensitizer exposure. The ATM inhibitor WSD0628 was combined with single or fractionated doses of radiation delivered to the oral cavity or esophagus of Friend Leukemia virus B (FVB) mice. The potentiation by WSD0628 was quantified by a sensitizer enhancement ratio (SER), which describes the changes in radiation tolerance for radiation combined with WSD0628 relative to radiation-only regimens. WSD0628 profoundly enhanced radiation-induced acute oral and esophageal toxicities. For oral mucosal toxicity, the enhancement by WSD0628 with 3 fractions of radiation resulted in an SER ranging from 1.3 (0.25 mg/kg) to 3.1 (7.5 mg/kg). For the 7.5 mg/kg combination, the SER increased with increasing number of fractions from 2.2 (1 fraction) to 4.3 (7 fractions) for oral toxicity and from 2.2 (1 fraction) to 3.6 (3 fractions) for esophageal toxicity, which reflects a loss of the normal tissue sparing benefit of fractionated radiation. These findings were used to develop a modified biologically effective dose model to determine alternative radiation schedules with or without WSD0628 that result in similar levels of toxicity. Successful radiosensitizer dose escalation to a maximally effective therapeutic dose will require careful deliberation of tumor site and reduction of radiation dose volume limits for organs at risk.
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies
Lalla, Anjana, Kelton, Kari , Piron, Cristiano, Gandhi, Pranav , Pozo‐Rosich, Patricia , Piron, Cristiano , Gandhi, Pranav , Pozo-Rosich, Patricia , Ailani, Jessica , Lalla, Anjana, Singh, Rashmi B. Halker , Holle, Dagny , Nagy, Krisztian

Cephalalgia | November 19, 2024 | Volume: 44 | Issue: 11 | Pages: No page available

10.1177/03331024241299377 | PMID 39558612 Get It

Background To evaluate the benefit-risk assessment of atogepant and calcitonin gene–related peptide (CGRP) monoclonal antibodies (mAbs) vs. placebo based on the number needed to treat (NNT) and the number needed to harm (NNH) in a blended episodic migraine and chronic migraine (EM + CM) population. Methods The NNT was calculated based on achievement of a ≥ 50% reduction in mean monthly migraine days (MMDs) from baseline across 12 weeks. The NNH was calculated using the proportion of participants reporting a discontinuation due to adverse events (AEs). The primary analysis included data from studies of atogepant, erenumab, galcanezumab, eptinezumab and fremanezumab. Results In the primary analysis, the calculated NNT for atogepant 60 mg vs. placebo was 4.2 (95% credible interval (CrI) = 3.1–6.7), which was the lowest relative to the CGRP mAbs in the blended EM + CM population. Participants who received atogepant 60 mg or fremanezumab showed the most favorable NNH values (−1010 (95% Crl = 44 to ∞ to number needed to benefit 80) for atogepant) resulting from lower rates of discontinuation due to AEs compared with those receiving placebo. Conclusions Atogepant demonstrated a favorable benefit-risk profile, with NNT and NNH values comparable (not statistically significant) with those of CGRP mAbs across all analyses.
Utilizing quantitative susceptibility mapping to differentiate primary lateral sclerosis from progressive supranuclear palsy: A case report
Sekiya, Hiroaki , Satoh, Ryota , Ali, Farwa , Whitwell, Jennifer L., Josephs, Keith A. , Josephs, Keith A , Sekiya, Hiroaki , Satoh, Ryota , Dickson, Dennis W. , Whitwell, Jennifer

Neuropathology | November 19, 2024 | Volume: 45 | Issue: 3 | Pages: 223-227

10.1111/neup.13015 | PMID 39557402 Get It

We report a patient who presented clinically with progressive supranuclear palsy (PSP) but was pathologically diagnosed as having primary lateral sclerosis (PLS) with magnetic resonance imaging (MRI) with a quantitative susceptibility mapping (QSM) protocol. A 70‐year‐old man was clinically diagnosed with PSP due to early falls and unresponsiveness to levodopa therapy. Postmortem pathological examination revealed mild loss of Betz cells, gliosis, and transactive response DNA binding protein of 43 kDa (TDP‐43)‐positive inclusions in the motor cortex, leading to the pathological diagnosis of PLS. To explore methods for differentiating PLS from PSP, ante‐mortem QSM images were visually and quantitatively assessed for abnormal increases in magnetic susceptibility in the motor cortex. Prussian blue and Luxol fast blue combined with periodic acid‐Schiff staining were also performed to understand the source of the susceptibility increases. QSM showed clear hyperintense signals in the motor cortex. Magnetic susceptibility in the motor cortex was higher in the PLS patient (Z = 4.7, p < 0.001) compared to normal controls and pathologically diagnosed PSP patients. Pathological examination of the region showed intracortical myelin loss, as well as iron deposition. Underlying pathological processes for the increased magnetic susceptibility include not only iron deposition but also intracortical myelin. Our case suggests that QSM is a potential tool to differentiate PLS from PSP, providing insights for accurate diagnosis and enhancing clinical decision‐making.
Pharmacist Medication Titration Program for Patients With Cardiac Sarcoidosis and Systolic Heart Failure: A Retrospective Cohort Study
Sykora, Daniel , Olson, Nicole, Kim, B Michelle , Bratcher, Melanie, Elwazir, Mohamed Y. , Young, Kathleen A. , Ryan, Sami, Brodin, Michelle, Anderson, Jan, Saunders, Jeremiah, Ezzeddine, Omar Abou, Bois, John P. , Giudicessi, John R. , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Churchill, Robert , Elwazir, Mohamed , Young, Kathleen , Abou Ezzeddine, Omar, Giudicessi, J R , Cooper, Leslie T , Rosenbaum, Andrew N , AbouEzzeddine, Omar F , Kim, B Michelle , Cooper, Leslie T.

Journal of the American Heart Association | November 18, 2024 | Volume: 13 | Issue: 24 | Pages: No page available

10.1161/jaha.124.038965 | PMID 39556701 Get It

Background A multidisciplinary approach improves guideline‐directed medical therapy in systolic heart failure (HF), but its efficacy in patients with HF due to cardiac sarcoidosis is unreported. Methods and Results In a retrospective cohort study, we reviewed 848 patients from our institutional cardiac sarcoidosis clinics, identifying those with a cardiac sarcoidosis diagnosis, HF (left ventricular ejection fraction <50%) at index evaluation, and echocardiograms within 90 days and 11 to 36 months. Patients were stratified by participation in a pharmacist‐led medication therapy management (MTM) program for guideline‐directed medical therapy optimization (MTM versus non‐MTM [NMTM]) without randomization. Demographics, left ventricular ejection fraction, guideline‐directed medical therapy (quantified by Kansas City Medical Optimization score), and immunosuppressive therapy were assessed. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular event–free survival (unplanned HF hospitalization, left ventricular assist device /heart transplant, or death). The final cohort included 111 patients (median age, 57 years; 34% women; 64% New York Heart Association class I–II); 43 (39%) were MTM and 68 (61%) were NMTM. Mean Kansas City Medical Optimization score was similar at index evaluation (MTM, 23.2; NMTM, 29.6; P =0.83). At follow‐up (median, 16 months), the Kansas City Medical Optimization score increased significantly in both groups (MTM, 23.2 to 74.8; P <0.001; NMTM, 29.6 to 58.7; P <0.001) but was higher in MTM ( P =0.001). Mean left ventricular ejection fraction trended toward higher values in MTM (44.4% versus 40.0%, P =0.05). The primary clinical outcome occurred in 1 MTM (2.3%) and 16 NMTM (23.5%) patients, with higher risk in NMTM (hazard ratio, 11.97 [95% CI, 1.58–90.54]; P =0.002). Conclusions In this retrospective cohort study, a pharmacist‐led MTM program was associated with favorable guideline‐directed medical therapy optimization and lower risk of adverse cardiovascular outcomes in patients with cardiac sarcoidosis with HF.
Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis
Paramasivan, Naveen Kumar , Karsten, Carley , Zahid, Anza , Kherbek, Haidara , Ζεκερίδου, Αναστασία , Sista, Sri Raghav, Dasari, Surendra , Mangioris, Georgios , Mills, John R. , Pittock, Sean J, Dubey, Divyanshu , Pittock, Sean J. , Dubey, Divyanshu , Pittock, S J , Masoud, Majed, Kherbek, Haidara , Zekeridou, Anastasia , Knight, Andrew M, McKeon, Andrew , Dubey, Divyanshu , Dubey, Divyanshu , Paramasivan, Naveen K , Masoud, Majed, Knight, Andrew M., McKeon, Andrew

Annals of Clinical and Translational Neurology | November 18, 2024 | Volume: 12 | Issue: 2 | Pages: 280-290

10.1002/acn3.52254 | PMID 39556523 Get It

AbstractObjectiveTo describe the phenotypes, oncological associations, biomarker profiles, and outcomes across different age groups in patients with ANNA1 (anti‐Hu) autoimmunity.MethodsA retrospective review of patients with ANNA1‐IgG in serum/CSF between January 1, 2001, and December 31,2019 was performed. Patients were classified into three groups based on the age of symptom onset. Phage immunoprecipitation sequencing (PhIP‐Seq) and neurofilament light chain (NfL) measurements were done in patient sera/CSF with archived samples.ResultsOf 122 patients, 81 (66%), 20 (16%), and 21 (17%) patients belonged to older adults, young adults, and pediatric groups, respectively. Lung cancer and neuromuscular presentations were more common in older adults (p < 0.001), while limbic encephalitis and neuroblastoma were more common in pediatric patients (p < 0.005). Most young adults (75%) did not have cancer identified. Proportions of patients with a favorable response to immunotherapy were 20%, 30%, and 52% among older adults, young adults, and pediatric groups, respectively. PhIP‐Seq demonstrated significant enrichment for ELAVL4 peptides especially for amino acids 240–289, in the majority of samples evaluated (36/67, 54%). ZIC and SOX2 peptides were significantly enriched in those with central nervous system presentations. Serum NfL levels were elevated in patients with cancer and those with poor long‐term outcomes.InterpretationYoung adults with ANNA1 autoimmunity phenotypically resembled older adults but rarely had an underlying cancer. Pediatric patients frequently presented with limbic encephalitis and neuroblastoma and often responded favorably to immunotherapy. Distinct antigenic signatures may underlie differences in clinical presentations. Serum NfL levels may be a biomarker of poor long‐term outcomes in ANNA1 autoimmunity.
Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis
Sabik, Joseph F. , Rao, Vivek , Dagenais, François, Moront, Michael G., Patel, Himanshu J. , Oh, Jae K. , Fukuhara, Shinichi , Labrousse, Louis , Günzinger, Ralf, Wu, Tianhua, Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martin, Günzinger, Ralf, Lange, Rudiger, Chu, Michael , Reardon, Michael J , Patel, Himanshu J , Labrousse, Louis , Ito, Saki , Chu, Michael W A , Reardon, Michael J. , Baig, Kamran M. , Ito, Saki , Klautz, Robert J.M. , Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martín , Günzinger, Ralf, Lange, Rudiger

European Journal of Cardio-Thoracic Surgery | November 18, 2024 | Volume: 67 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezae414 | PMID 39565905 Get It

Abstract OBJECTIVES Safety, efficacy and durability are important considerations when selecting a bioprosthesis for aortic valve replacement (AVR). This study assessed 7-year clinical outcomes and haemodynamic performance of the Avalus bioprosthesis. METHODS Patients indicated for surgical AVR were enrolled in this prospective, nonrandomized trial, conducted across 39 sites globally. The primary end-point of this analysis was freedom from surgical explant or percutaneous valve-in-valve reintervention due to structural valve deterioration (SVD) at 7 years of follow-up, determined using Kaplan–Meier (KM) analysis. We also evaluated a composite end-point of SVD and/or severe haemodynamic dysfunction requiring reintervention. Survival, valve-related safety events and haemodynamic performance were assessed. Deaths and safety events were adjudicated by an independent clinical events committee. RESULTS A total of 1132 patients underwent surgical AVR. Mean age was 70 years; 854 patients (75%) were men. The mean STS risk of mortality was 2.0 ± 1.4%, and 659 patients (58%) had a New York Heart Association classification of I/II. One or more concomitant procedures were performed in 577 patients (51%). At 7 years, the Kaplan–Meier rate of freedom from SVD/severe haemodynamic dysfunction requiring reintervention was 1.2% (0.5–2.5%) with no cases adjudicated as SVD. The survival rate was 82.6% (79.5–85.0%). The KM event rate was 5.7% (4.3–7.7%) for reintervention, 6.3% (4.9–8.3%) for endocarditis and 0.4% (0.1–1.1%) for valve thrombosis. Mean aortic gradient, dimensionless velocity index and effective orifice area were 13.8 ± 5.9 mmHg, 0.42 ± 0.09 and 1.99 ± 0.53 cm2, respectively. CONCLUSIONS This analysis demonstrated excellent durability of the Avalus valve with good clinical outcomes and stable haemodynamic performance through 7 years of follow-up.
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Zile, Michael R. , Borlaug, Barry A. , Kramer, Christopher M. , Baum, Seth J. , Litwin, Sheldon E. , Menon, Venu , Ou, Yang , Weerakkody, Govinda J. , Hurt, Karla, Murakami, Masahiro, Group, for the SUMMIT Trial Study, Murakami, Masahiro , Packer, Milton , Borlaug, Barry A , Zile, Michael R , Kanu, Chisom , Packer, Milton , Group, for the SUMMIT Trial Study

Circulation | November 18, 2024 | Volume: 151 | Issue: 10 | Pages: 656-668

10.1161/circulationaha.124.072679 | PMID 39556714 Get It

BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients. METHODS: We randomized (double-blind) 731 patients with class II to IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m 2 to tirzepatide (titrated up to 15 mg SC weekly; n=364) or placebo (n=367) added to background therapy for a median of 104 weeks (quartile 1, 66; quartile 3, 126 weeks). The primary end points were whether tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The current expanded analysis included sensitivity analyses of the primary end points, 6-minute walk distance, EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health score, New York Heart Association class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and 6-minute walk distance. RESULTS: Patients were 65.2±10.7 years of age; 53.8% (n=393) were female; body mass index was 38.2±6.7 kg/m 2 ; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 53.5±18.5; 6-minute walk distance was 302.8±81.7 m; and 53% (n=388) had a worsening heart failure event in the previous 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time to first event (hazard ratios, 0.41–0.67). At 52 weeks, tirzepatide increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 6.9 points (95% CI, 3.3–10.6; P <0.001), 6-minute walk distance 18.3 meters (95% CI, 9.9–26.7; P <0.001), and EQ-5D-5L 0.06 (95% CI, 0.03–0.09; P <0.001). The tirzepatide group shifted to a more favorable Patient Global Impression of Severity Overall Health score (proportional odds ratio, 1.99 [95% CI, 1.44–2.76]) and New York Heart Association class (proportional odds ratio, 2.26 [95% CI, 1.54–3.31]; both P <0.001) and required fewer heart failure medications ( P =0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio, 1.63 [95% CI, 1.17–2.28]; P =0.004). CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being; and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04847557.
Retrospective analysis of antimicrobial susceptibility profiles of non- diphtheriae Corynebacterium species from a tertiary hospital and reference laboratory, 2012–2023
Khodadadi, Ryan B. , Zein, Said El , Rivera, Christina G. , Schuetz, Audrey N. , Saleh, Omar Abu , Fida, Madiha , El Zein, Said , Rivera, Christina G , Schuetz, Audrey N , Abu Saleh, Omar M, Fida, Madiha , Khodadadi, Ryan B , Stevens, Ryan W.

Journal of Clinical Microbiology | November 18, 2024 | Volume: 62 | Issue: 12 | Pages: No page available

10.1128/jcm.01199-24 | PMID 39555924 Get It

ABSTRACT A total of 1,925 Corynebacterium isolates were tested for antimicrobial susceptibility at the Mayo Clinic Microbiology laboratory (Rochester, Minnesota) from January 2012 to March 2023, with C. striatum (35.6%) and C. amycolatum (24.4%) identified as the predominant species. Species known to potentially carry diphtheria toxin were excluded. Common sources of isolation included skin and soft tissue (56.8%), bone and/or native joint synovial fluid (14.2%), urine (13.1%), sputum (6.1%), and blood (5.9%). For penicillin, susceptibility decreased from 47.5% (58 of 122) in 2012 to 20.6% (14 of 68) in 2023. Isolates also showed a decrease in susceptibility to erythromycin from 22.4% (26 of 116) in 2012 to 13.2% (9 of 68) in 2023. Susceptibility to trimethoprim-sulfamethoxazole averaged around 50% throughout the period. Notably, linezolid and vancomycin were universally effective in vitro against all species. The highest susceptibility rates among tested oral agents were to linezolid and doxycycline for non- C . striatum species. Daptomycin minimal inhibitory concentrations (MICs) of >256 µg/mL were observed for one C. amycolatum isolate, one C. tuberculostearicum isolate, and for seven C. striatum isolates, all from patients with prior daptomycin exposure. Daptomycin MICs of 2 µg/mL (nonsusceptible) were observed in one C. striatum isolate recovered from a daptomycin-naïve patient and in six C. jeikeium isolates, from both daptomycin-exposed and non-exposed patients. Significant variation in susceptibility profiles across different Corynebacterium species underscores the importance of performing antimicrobial susceptibility testing to guide effective treatment. Moreover, multidrug resistance observed in C. striatum poses substantial therapeutic challenges especially in patients requiring prolonged or chronic antibiotic suppression.
Radiographic Enhancement of Lymph Nodes 9 Months after Omental Lymph Node Transfer
Shrout, Max A., Plonkowski, Alexander T., Morris, Bryn E., Rebecca, Alanna M. , Plonkowski, Alexander T. , Flug, Jonathan A.

Plastic and Reconstructive Surgery - Global Open | November 18, 2024 | Volume: 12 | Issue: 11 | Pages: e6305

10.1097/gox.0000000000006305 | PMID 39559267 Get It

Lymphedema is a frequent complication of breast cancer treatment. As the survival rates of breast cancer continue to increase, the number of women with lymphedema will also increase. Surgical treatment of lymphedema has made significant advances during the past 20 years, and our understanding of these procedures continues to evolve. Vascularized lymph node transfer is an increasingly popular option for surgical treatment of lymphedema; however, the mechanism behind symptomatic relief is not fully understood. A proposed theory for improvement in lymphedema symptoms is lymphangiogenesis and spontaneous regeneration of lymphatic vessels, the timing and degree of which are not well defined. We present the case of a 40-year-old woman with a 10-year history of right upper extremity lymphedema secondary to bilateral mastectomy and right axillary lymph node dissection, who subsequently underwent vascularized omental lymph node transfer and lymphovenous bypass with radiographic evidence of spontaneous lymphatic reconnection within 9 months. To our knowledge, this is the earliest reported radiographic evidence of lymphatic regeneration in a human subject to date, adding to the growing body of evidence to support the therapeutic benefits of vascularized lymph node transfers.
Trends and disparities in age, sex, ethnoracial background, and urbanization status in adult mortality due to thoracic aortic aneurysm: a retrospective nationwide study in the United States
Goyal, Aman , Saeed, Humza , Shamim, Urooj, Siddiqui, Momina R., Abdullah, Abdullah , Arshad, Muhammad Khubaib , Jain, Hritvik , Daoud, Mohamed , Khan, Rozi , Bansal, Kamna , Goyal, Aman , Siddiqui, Momina R.

International Journal of Surgery | November 18, 2024 | Volume: 110 | Issue: 12 | Pages: 7647-7655

10.1097/js9.0000000000002150 | PMID 39806735 Get It

Introduction: Thoracic aortic aneurysms (TAA) are a significant health concern, with the true prevalence likely underestimated due to undiagnosed cases. Outcomes in TAA are influenced by factors like age, sex, and comorbidities such as hypertension. This study examines mortality trends and disparities associated with TAA in US adults. Methodology: This study analyzed death certificates from 1999 to 2020 using the CDC WONDER Database to identify TAA-related deaths in individuals aged 25 and older using ICD-10 codes I71.1 and I71.2. Age-adjusted mortality rates (AAMRs) per 1 000 000 and annual percent changes (APCs) were calculated and stratified by year, sex, age group, race/ethnicity, region, and urbanization status. Results: Between 1999 and 2020, 47 136 TAA-related deaths were reported among US adults. The AAMR decreased from 16.2 to 8.2 per 1 000 000, with a significant decline from 1999 to 2013 (APC: −5.00; 95% CI: −5.54 to −4.54; P<0.001). Older adults had the highest AAMRs at 44.6 per 1 000 000. Men had higher AAMRs than women (11.2 vs. 9). AAMRs were highest among non-Hispanic (NH) Black (11), followed by NH White (10.3), NH Asian or Pacific Islander (9.5), NH American Indian or Alaska Native (7.8), and Hispanic (5.2) populations. Nonmetropolitan areas had higher AAMRs than metropolitan areas (11 vs. 9.8). Conclusions: The analysis showed a significant decline in TAA mortality since 1999, with recent stabilization. However, disparities persist, with higher AAMRs among men, older adults, NH Black adults, and nonmetropolitan residents, highlighting the need for targeted and equitable interventions.